TOI Form 4: CEO equity grant boosts stake to 1.8M shares

Rhea-AI Filing Summary

The Oncology Institute, Inc. (TOI) reported that its Chief Executive Officer acquired additional common stock through a stock-based award. On 11/17/2025, the officer received 6,464 shares of common stock at a stated price of $0.00 per share, increasing their directly held stake to 1,799,984 shares.

The filing explains that these 6,464 shares represent restricted stock units (RSUs) that were fully vested upon grant, after shares were withheld to cover tax obligations. This is a routine equity compensation event that aligns the CEO’s interests more closely with those of other shareholders.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Virnich Daniel

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	6,464	$0.00	--

Holdings After Transaction: Common Stock — 1,799,984 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Virnich Daniel

(Last) (First) (Middle)

C/O THE ONCOLOGY INSTITUTE INC.

18000 STUDEBAKER RD, SUITE 800

(Street)

CERRITOS CA 90703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/17/2025		A		6,464(1)	A	$0.00	1,799,984	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents RSU awards that were fully vested upon grant, net of withholding tax obligations.

	/s/ Mark Hueppelsheuser, Attorney-in-Fact for Daniel Virnich	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did TOI report in this Form 4?

The Oncology Institute, Inc. reported that its Chief Executive Officer acquired 6,464 shares of common stock on 11/17/2025 through a restricted stock unit award.

At what price were the 6,464 TOI shares acquired by the CEO?

The 6,464 shares of The Oncology Institute, Inc. common stock were acquired at a stated price of $0.00 per share as part of an RSU grant.

How many TOI shares does the reporting person own after this transaction?

Following the reported RSU transaction, the reporting person beneficially owns 1,799,984 shares of The Oncology Institute, Inc. common stock directly.

What is the relationship of the reporting person to The Oncology Institute, Inc. (TOI)?

The reporting person is an officer of The Oncology Institute, Inc., serving as its Chief Executive Officer.

What type of equity award did the TOI CEO receive?

The CEO received restricted stock units (RSUs), which the filing notes were fully vested upon grant after accounting for shares withheld for tax obligations.

Is this TOI Form 4 filed for one or multiple reporting persons?

This Form 4 is filed by one reporting person, as indicated in the filing’s certification section.